From CNBC: 2024-06-10 07:53:11

Moderna’s combination vaccine targeting Covid-19 and the flu showed higher efficacy than standalone shots in a late-stage trial, leading the race among vaccine makers. Plans to file for regulatory approval this summer with hopes of market entry in 2025, simplifying protection against respiratory viruses. Safety and tolerability were acceptable with mild side effects reported. Pfizer, BioNTech, and Novavax are also developing combination shots targeting Covid and the flu.



Read more at CNBC: Moderna combination Covid, flu vaccine shows positive late-stage data